News

From Stagnation To Surge: Gilead Sciences Is Entering Its Next Growth Wave

Gilead Sciences is accelerating its growth rate and Yeztugo might be another major blockbuster. GILD stock is still trading ...
StockStory.org on MSN1d

Why Gilead Sciences (GILD) Shares Are Sliding Today

Shares of biopharmaceutical company Gilead Sciences (NASDAQ:GILD) fell 3.5% in the morning session after reports that CVS Health will not be adding the company's new HIV prevention drug, Yeztugo, to ...
STAT1d

Pharmalittle: We’re reading about Gilead’s HIV drug, FDA speeding review of a rare disease drug, and more

CVS Health will not add Gilead Sciences' new HIV prevention drug to its commercial plans for now, despite the medicine's ...

Gilead Sciences Lifts Annual Outlook As Yeztugo Launch Nears

Gilead Sciences (NASDAQ:GILD) announced its second-quarter 2025 earnings and revised annual outlook after the market closed on Thursday. The HIV drug maker reported adjusted earnings of $2.01 per ...
StockStory.org on MSN9d

Gilead Sciences’s Q2 Earnings Call: Our Top 5 Analyst Questions

Gilead Sciences delivered a better-than-expected second quarter, propelled by the strong performance of its HIV portfolio and ...

Gilead posts flat second quarter profit, ups full-year outlook on strong HIV sales

Gilead Sciences on Thursday reported flat second-quarter earnings on slightly higher revenue and raised its full-year financial outlook, citing better-than-expected sales of HIV drugs.